LENZ Therapeutics, Inc. (LENZ) financial statements and ratios from SEC XBRL: revenue $19.09M (TTM), net margin -430.3%, revenue growth 123.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $19.09M |
| Net Margin | -430.3% |
| Revenue Growth (YoY) | 123.2% |
| EPS Growth (YoY) | 21.8% |
| FCF Growth (YoY) | 16.9% |
| Price / Book | 0.67 |
| Price / Sales | 6.75 |
| FCF Yield | -120.0% |
| Altman Z-Score | 3.23 (safe) |
| Sector P/E (Healthcare) | 21.7 |
LENZ overview · LENZ earnings · LENZ KPIs · LENZ investor relations · LENZ ownership · LENZ peers · LENZ filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.